Open Access Open Access  Restricted Access Subscription or Fee Access

Benign ProstaticHyperplasia–EnhancementinPrevalence,EtiologyandManagement

Unithirumala Amitha, Sathish ., Rasa Gnaneshwer

Abstract


The goal is to learn more about the prevalence, etiology, treatment, and complications of benign prostatic hyperplasia. This is a 6-month retrospective study that covers people who have been diagnosed with BPH. The prevalence, etiology, management, and consequences of benign prostatic hyperplasia were investigated. By recognizing lower urinary tract symptoms and identifying an enlarged prostate, men can receive early treatment and limit the effects of benign prostatic hyperplasia. Benign prostatic hyperplasia affects 67.67 percent of males. There were 85 patients in the current study, with a mean age of 49.18 11.40 years and a range of ages of 60 and higher (64.3 percent) (31-82 years). Patients with mild symptoms of benign prostatic hyperplasia accounted for 24.0 percent of the total, whereas those with moderate and severe symptoms accounted for 14.3 percent and 3.7 percent, respectively. The prevalence of benign prostatic hyperplasia was significantly higher in those over the age of 60. (64.3 %). According to the data, there were no statistically significant differences in educational and occupational levels. Physical exercise. On the other hand, fruit intake, vegetable consumption, and vegetable intake were factors that significantly reduced the risk of benign prostatic hyperplasia. Most of the patients with 91% have been treated with surgeries like Transurethral resection of the prostate, laser therapy and proctectomy and rest 9% were treated through medications like non-selective alpha blockers, anticholinergic agents, selective alpha blockers. 5-alpha reductase inhibitors with antibiotics like Trimethoprim, sulfamethoxazole, and Doxycycline. With a greater understanding of the pathophysiology of clinical BPH, patients can be better selected for customized and tailored care, as well as more cost-effective therapy. With age, we discovered an increasing tendency in the prevalence of LUTS/BPH. It differed by marital status, social status, and geographic location. Obesity, diabetes, and high fasting plasma glucose are all risk factors for benign prostatic hyperplasia. There is no method to prevent benign prostatic hyperplasia, according to researchers. Men with risk factors for benign prostatic hyperplasia should discuss any lower urinary tract symptoms with their doctor, as well as the need for regular prostate checks. By recognizing lower urinary tract symptoms and identifying an enlarged prostate, men can receive early treatment and limit the effects of benign prostatic hyperplasia. However, for patients with confirmed benign prostatic hyperplasia, several lifestyle adjustments, drugs, minimally invasive procedures, and surgeries have proven to be useful.

 


Keywords


Benignprostatichyperplasia,Prevalence,Etiology,Treatment,Complications

Full Text:

PDF

References


AuffenbergGB,HelfandBT,McVaryKT.Establishedmedicaltherapyforbenignprostatichyperplasia.UrolClinNorthAm2009;36(4):443–59.,

McNealJ.Pathologyofbenignprostatichyperplasia.Insightintoetiology.UrolClinNorthAm1990;17(3):477–86.

McVaryKT,RoehrbornCG,AvinsAL,BarryMJ,BruskewitzRC,DonnellRF,etal.UpdateonAUAguidelineonthemanagementofbenignprostatichyperplasia.JUrol2011;185(5):1793–803.

StroupSP,Palazzi-ChurasK,KoppRP,ParsonsJK.Trendsinadverseeventsofbenignprostatichyperplasia(BPH)intheUSA,1998to2008.BJUInt2012;109(1):84–7.

TaylorBC,WiltTJ,FinkHA,LambertLC,MarshallLM,HoffmanAR,etal.Prevalence,severity,andhealthcorrelatesoflowerurinarytractsymptomsamongoldermen:TheMrOSstudy.Urology2006;68(4):804–9.

ParsonsJK,MougeyJ,LambertL,WiltTJ,FinkHA,GarzottoM,etal.Lowerurinarytractsymptomsincreasetheriskoffallsinoldermen.BJUInt2009;104(1):63–8.

BoschJ.L.,TillingK.,BohnenA.M.,BangmaC.H.,DonovanJ.L.-Establishingnormalreferencerangesforprostatevolumechangewithageinthepopulation-basedKrimpen-study:predictionoffutureprostatevolumeinindividualmen.Prostate.2007;67(16):1816–1824.

WeiJT,CalhounE,JacobsenSJ-UrologicdiseasesinAmericaproject:benignprostatichyperplasia.JUrol2005;173(4):1256–1261

PatelND,ParsonsJK.-Epidemiologyandetiologyofbenignprostatichyperplasiaandbladderoutletobstruction.IndianJournalofUrology,2014Apr;30(2):170–6.

RaoCN,SinghMK,ShekharT,etal.-Causesoflowerurinarytractsymptoms(LUTS)inadultmales.IndianJUrol.2004;20(2):95–100

AdegunPT,PopoolaAA.-Asurveyofbenignprostatichyperplasia(BPH)amongstpatientswithprostaticdisordersinAdo-Ekiti,Nigeria.NigMedPract.2011;60(3–6):38–42

BerhanuNA.-Thesafetyandefficacyoftrans-vesicalprostatectomydoneataprimarygeneralhospitalsettinginEthiopia.EastandCentralAfricanJournalofSurgery.2008:3(2):53–56.

Jensen,K.M.,Jorgensen,J.B.,Mogensen,P.&Bille-Brahe,N.E.-Someclinicalaspectsofuroflowmetryinelderlymales.Apopulationsurveys.ScandJUrolNephrol.1986;20(2):93–9.

Chokkalingam,A.P.,E.D.Yeboah,A.DeMarzo,G.NettoandK.Yuetal.,2012.-PrevalenceofBPHandlowerurinarytractsymptomsinWestAfricans.ProstateCancerProstateDis.,2012:15(2):170–176

Safarinejad,M.R.-Prevalenceofbenignprostatichyperplasiainapopulation-basedstudyinIranianmen40yearsoldorolder.IntUrolNephrol.2008;40(4):921–31.

MannarinoMR,DiFilippoF,PirroM(2012)-Obstructivesleepapneasyndrome.EurJInternMed.2012Oct;23(7):586–93.

KullisaarT,TurkS,PunabM,MandarR(2012)-Oxidativestress–causeorconsequenceofmalegenitaltractdisorders?Prostate.2012Jun15;72(9):977–83.

ChouPS,ChangWC,ChouWP,LiuMN,LaiCL,LiuCK,KuYC,TsaiSJ,ChouYH,ChangWP.-IncreasedRiskofBenignProstateHyperplasiainSleepApneaPatients:ANationwidePopulation-BasedStudy.PLOSONE.2014Mar25;9(3):e93081.

CakirOO,McVaryKT.-LUTSandSleepDisorders:EmergingRiskFactor.CurrUrolRep.2012Dec;13(6):407–412.

LeeW,NagubadiS,KrygerMH,MokhlesiB(2008)-EpidemiologyofObstructiveSleepApnea:aPopulation-basedPerspective.ExpertRevRespirMed.2002May1;165(9):1217–39.

PlateEA,RimmEB,KawachiI,ColditeGA,StampferMJ,WillettWC,GiovannuccE.-AlcoholConsumption,CigaretteSmoking,andRiskofBenignProstaticHyperplasia.AmJEpidemiol1999;149(2):106-115

RobertsR,JacobsenS,RhodesT,etal.-Cigarettesmokingandprostatism:abiphasicassociation?Urology1994;43(6):797-801

LeeE,ParkM,ShinC,etal.-Ahigh-riskgroupforprostatism:apopulation-basedepidemiologicalstudyinKorea.BrJUrol1997;79(5):736–741

DaiWS,GutaiJP,KullerLH,etal.-Cigarettesmokingandserumsexhormonesinmen.AmJEpidemiol1988;128(4):796-805

FieldAE,ColditzGA,WillettWC,etal.-Therelationofsmoking,age,relativeweight,anddietaryintaketoserumadrenalsteroids,sexhormones,andsexhormone-bindingglobulininmiddle-agedmen.JClinEndocrinolMetab1994;79(5):1310–16

UniversityofMarylandMedicalCenter(2016).ProstateEnlargement(BPH).Availableonlineat:https://www.umms.org/ummc/health-services/prostate/services/enlargement-bph

WatsonSandKimS(2015).-WhatAretheRiskFactorsforBPH?

SandaMG,BeatyTH,StutzmanRE,ChildsB,WalshPC.-Geneticsusceptibilityofbenignprostatichyperplasia.JUrol1994;152(1):115–9.

ParsonsJK,SarmaAV,McVarryK,WeiJT.-Obesityandbenignprostatichyperplasia:clinicalconnections,emergingetiologyparadigmsandfuturedirections.JUrol2013;189(1Suppl):S102-S106.

GiovannucciE,RimmEB,ChuteCG,etal.-Obesityandbenignprostatichyperplasia.AmJEpidemiol1994;140(11):989–1002

DahleSE,ChokkalingamAP,GaoYT,etal.-Bodysizeandserumlevelsofinsulinandleptininrelationtotheriskofbenignprostatichyperplasia.JUrol2002;168(2):599–604.

KristalAR,ArnoldKB,SchenkJM,etal.-Race/ethnicity,obesity,healthrelatedbehaviorsandtheriskofsymptomaticbenignprostatichyperplasia:resultsfromtheprostatecancerpreventiontrial.JUrol2007;177(4):1395–1400.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Research & Reviews: Journal of Medicine